Allergy to Phleum pratense and Dactylis glomerata.
Conditions
Brief summary
The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of each allergenic extract (Phleum pratense and Dactylis glomerata), as well as those induced by positive (histamine) and negative controls, through the prick test.
Detailed description
Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject., Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR).
Interventions
DRUGPrick test of enriched Phleum pratense pollen extract
DRUGPrick test of enriched Dactylis glomerata pollen extract
Sponsors
Inmunotek S.L.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of each allergenic extract (Phleum pratense and Dactylis glomerata), as well as those induced by positive (histamine) and negative controls, through the prick test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject., Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR). | — |
Countries
Spain
Outcome results
None listed